Pfizer Inc. (PFE.DE)
Pfizer Inc. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $22.74, down 1.39% on the session, giving a market capitalisation of $129.61B. Its beta of 0.31 implies it has historically moved less than the broad market.
Pfizer Inc. operates as a leading global biopharmaceutical company, overseeing the complete lifecycle of its products from discovery and development to manufacturing, marketing, and distribution. Its expansive portfolio features a broad array of medicines and vaccines designed to address diverse therapeutic needs. These include treatments for cardiovascular, metabolic, and women's health conditions, along with an oral therapy for COVID-19 and various anti-infective and sterile injectable drugs. The company also specializes in biologics, small molecules, immunotherapies, and biosimilars for areas such as pneumococcal and meningococcal diseases, tick-borne encephalitis, chronic immune and inflammatory disorders, amyloidosis, hemophilia, and endocrine diseases. Notable brands spanning these categories include Premarin, Eliquis, Ibrance, Xtandi, Paxlovid, Comirnaty, Prevnar, Xeljanz, and Vyndaqel. In addition to its core pharmaceutical business, Pfizer offers contract manufacturing services. Its clientele is extensive, comprising hospitals, clinics, individual providers, pharmacies, wholesalers, retailers, government entities, and disease prevention centers. The company actively maintains strategic collaboration agreements with numerous partners, including Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Myovant Sciences Ltd., Merck KGaA, Valneva SE, BioNTech SE, and Arvinas, Inc. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Pfizer Inc. is most often compared with the following Healthcare names: